Steroid Crystal Forms for Stable GABAA Drug Development
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug formulations for neuropsychiatric disorders, such as anxiety, depression, and schizophrenia, do not fully leverage the potential of GABA(A) receptor modulation, and there is a need for crystal forms of steroid compounds that exhibit improved physical and chemical properties for better pharmaceutical use.
Innovation Solution
Development of distinct crystal forms (A, B, C, D, E, F, and G) of a steroid compound, characterized by specific X-ray powder diffraction patterns, prepared through various methods including solvent-based and temperature-controlled processes, ensuring solvate-free and thermally stable forms suitable for pharmaceutical applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a steroid compound is used for neuropsychiatric disorder treatment, then GABA(A) receptor modulation efficacy is achieved, but the physical and chemical properties need improvement for better pharmaceutical use
Solution Approach 1:
The patent applies parameter changes by developing multiple crystal forms (polymorphs) of the steroid compound, each with distinct X-ray powder diffraction patterns and physical properties. By changing the crystalline structure parameters while maintaining the chemical composition, the invention achieves improved pharmaceutical properties such as stability, solubility, and manufacturability without altering the core medicinal activity at the GABA(A) receptor
Solution Approach 2:
The invention utilizes phase transitions by creating different solid-state crystal forms of the same steroid compound. Each crystal form represents a different phase arrangement of molecules in the solid state, characterized by unique diffraction patterns. These phase transitions enable optimization of pharmaceutical properties while preserving the therapeutic efficacy for neuropsychiatric disorders
2Reliability
If multiple crystal forms are developed, then pharmaceutical suitability is improved, but the complexity of characterization and selection increases
Solution Approach 1:
The patent employs characteristic X-ray powder diffraction patterns as unique identifiers for each crystal form, analogous to color changes as fingerprints. Each polymorph exhibits a distinct diffraction pattern with specific peak positions and intensities, enabling straightforward characterization and identification of the desired crystal form without complex analytical procedures
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new crystal forms provide improved stability and suitability for industrial production, addressing the need for effective neuropsychiatric disorder treatments with enhanced properties.
Implementation Method 1
adding the compound of Formula I into an organic solvent to achieve complete dissolution
Implementation Method 2
lowering the temperature to induce precipitation
Implementation Method 3
obtaining a solid after centrifugation
Implementation Method 4
the X-ray powder diffraction pattern thereof has characteristic peaks at 2θ values of 8.1°±0.2°, 11.7°±0.2°, 13.5°±0.2°, 16.2°±0.2°, and 17.6°±0.2°
Data Source
Figure 1A~1B
Figure 1C
Figure 1D
AI summary
The purpose of the present invention is to provide a crystal form of a steroid compound, a pharmaceutical composition and the use thereof in the preparation of a drug for diseases related to a GABAA receptor. Compared with the prior art, the crystal form provided in the present invention has one or more improved properties, and has great significance in further development of the drug.